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Background: Evidence is lacking to inform providers’ and patients’ decisions about many common treatment
strategies for patients with end stage renal disease (ESRD).
Methods/design: The DEcIDE Patient Outcomes in ESRD Study is funded by the United States (US) Agency for
Health Care Research and Quality to study the comparative effectiveness of: 1) antihypertensive therapies, 2) early
versus later initiation of dialysis, and 3) intravenous iron therapies on clinical outcomes in patients with ESRD.
Ongoing studies utilize four existing, nationally representative cohorts of patients with ESRD, including (1) the
Choices for Healthy Outcomes in Caring for ESRD study (1041 incident dialysis patients recruited from October 1995
to June 1999 with complete outcome ascertainment through 2009), (2) the Dialysis Clinic Inc (45,124 incident
dialysis patients initiating and receiving their care from 2003–2010 with complete outcome ascertainment through
2010), (3) the United States Renal Data System (333,308 incident dialysis patients from 2006–2009 with complete
outcome ascertainment through 2010), and (4) the Cleveland Clinic Foundation Chronic Kidney Disease Registry
(53,399 patients with chronic kidney disease with outcome ascertainment from 2005 through 2009). We ascertain
patient reported outcomes (i.e., health-related quality of life), morbidity, and mortality using clinical and
administrative data, and data obtained from national death indices. We use advanced statistical methods (e.g.,
propensity scoring and marginal structural modeling) to account for potential biases of our study designs. All data
are de-identified for analyses. The conduct of studies and dissemination of findings are guided by input from
Stakeholders in the ESRD community.
Discussion: The DEcIDE Patient Outcomes in ESRD Study will provide needed evidence regarding the effectiveness
of common treatments employed for dialysis patients. Carefully planned dissemination strategies to the ESRD
community will enhance studies’ impact on clinical care and patients’ outcomes.* Correspondence: lboulwa@jhmi.edu
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End stage renal disease (ESRD) is a significant and grow-
ing public health problem with increasing incidence and
prevalence in the United States and worldwide [1].
Patients with ESRD have rates of cardiovascular, cere-
brovascular, and infectious morbidity that are up to sev-
eral times greater than people in the general population,
as well as worse quality of life [2-10]. As a result, the
cost of caring for patients with ESRD is exceedingly
high, amounting for over $21 billion total in 2007 and
approximately 6% of total Medicare expenditures [1].
Despite the intensity and cost of care for patients with
ESRD, little is known about the impact of many com-
mon clinical management strategies that are intended to
improve health outcomes in ESRD [11]. In the absence
of rigorous evidence to guide clinical practice, many
strategies employed to treat common illnesses in the
general public have been adapted to treat the ESRD
population, with unclear effects on patients’ clinical out-
comes [11-18]. As a result, clinicians and patients are
unsure about which of these strategies are best. Rigorous
research on the effectiveness of common treatment
strategies for patients with ESRD could help improve de-
cision-making, the quality of ESRD care and patients’
health.
As part of its Effective Health Care Program, the
Agency for Healthcare Research and Quality (AHRQ)
supports the Developing Evidence to Inform Decisions
about Effectiveness (“DEcIDE”) Network to conduct
“studies on the outcomes, effectiveness, safety and use-
fulness of medical treatments and services” [19]. In
2009, the Effective Health Care Program received fund-
ing through the American Recovery and Reinvestment
Act (ARRA) to enhance its’ efforts to perform high-
quality comparative effectiveness studies in priority
areas. [20] The DEcIDE Patient Outcomes in End Stage
Renal Disease Study was commissioned with these funds
to better understand the comparative effectiveness of
different, commonly employed treatment strategies on
improving cardiovascular disease (CVD) and other im-
portant health outcomes among patients with ESRD, in-
cluding: (1) antihypertensive medication regimens, (2)
initial timing of dialysis initiation, and (3) iron manage-
ment strategies. In this paper, we describe the general
approach to comparative effectiveness studies employed
in the DEcIDE Patient Outcomes in End Stage Renal
Disease Study.
Methods/design
The study is being conducted through collaboration of
researchers at five centers (Johns Hopkins University
(coordinating center), Tufts University Medical Center,
Minneapolis Medical Research Foundation, the Univer-
sity of California, San Francisco, and the ClevelandClinic Foundation), which are conducting several obser-
vational “sub-studies” addressing the three comparative
effectiveness questions identified by AHRQ for investiga-
tion (aims and hypotheses in Table 1). Sub-studies draw
data from up to four nationally representative linked
data sources capturing the clinical care and outcomes
of patients with chronic kidney disease (CKD) or
ESRD and utilize rigorous methodology to compare
the effectiveness of kidney disease treatment strategies.
Data sources provide primary data (e.g., from chart
reviews and from patient report), treatment-level clin-
ical data (e.g., extracted from electronic health
records), and insurance claims (e.g., hospitalization
dates) collected in the course of CKD and dialysis
care.
Consistent with the goals of comparative effectiveness
research to perform studies that are relevant to
decision-makers in ESRD care, we have engaged an Ex-
pert Stakeholder Group representing key decision-
makers (including patients, health care providers, policy
makers, and regulators) within the ESRD community in
an ongoing fashion.
Common data sources
Four main data sources from which sub-studies derive
their data comprise representative US patient popula-
tions with kidney disease that are followed through ac-
tive and passive means until death. Cohorts are also
linked to (or are composed of ) registry data and Centers
for Medicare and Medicaid Services (CMS) claims gen-
erated during the course of ESRD care. Data are linked
to national death data sources to ascertain patients’ vital
status and underlying cause of death. (Tables 2 and 3).
Choices for healthy outcomes in caring for End-stage renal
disease (CHOICE) study
CHOICE is a longitudinal observational cohort study of
1,041 incident dialysis patients originally funded by
AHRQ to measure several aspects of patients’ experi-
ences and outcomes related to their choice of renal re-
placement therapy [21]. CHOICE includes a highly
demographically diverse sample of patients cared for
around the US in urban and rural settings, and receiving
peritoneal dialysis or in-center hemodialysis. The
CHOICE population (initial enrollment in 1995, with
ongoing passive follow-up) has more detailed informa-
tion about comorbidity, laboratory data, process of care,
and clinical outcomes than registries and other retro-
spective data sources, enhancing its benefits for use in
effectiveness studies [22]. CHOICE data are linked to
the USRDS registry to obtain information on patients’
health conditions and health care utilization. CHOICE
data are also linked to the National Death Index to con-
firm patients’ vital status and cause-specific mortality,
Table 1 Specific aims of sub-studies in the DEcIDE Patient Outcomes in End Stage Renal Disease Study
Sub-Study Specific Aim
1. Antihypertensive management a. To assess the comparative effectiveness of ACE inhibitors/ARBs , Beta Blockers, and Calcium
Channel Blockers in preventing all cause and cardiovascular disease (CVD) mortality among dialysis patients
b. To assess the comparative effectiveness of ACE inhibitors/ARBs, Beta Blockers and Calcium Channel
Blockers in preventing morbidity (CVD events, all cause hospitalizations, quality of life, worsening disability)
among patients on dialysis
2. Timing of dialysis initiation a. To assess the comparative effectiveness of early versus conventional dialysis initiation on
risk of all cause and cardiovascular mortality
b. To assess the comparative effectiveness of early versus conventional dialysis initiation on morbidity
(cardiovascular events, all cause and infectious hospitalizations, health-related quality of life,
comorbid disease control, and nutritional status)
3. Intravenous iron for anemia
management
a. To compare the effectiveness of iron dosing strategies (regular maintenance therapy versus
intermittent ‘as needed’ therapy) on anemia management
b. To assess the comparative effectiveness of lower versus higher cumulative IV iron doses on
CVD-related hospitalization and mortality, infection-related hospitalization and mortality, all cause mortality,
and quality of life
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Dialysis Clinic, Inc (DCI)
DCI is the largest non-profit provider of dialysis care
and third largest dialysis provider in the US, serving
approximately 13,000 patients at 209 dialysis facilities
in 27 states. The population of patients within DCI is
diverse and is demographically representative of the US
dialysis population, with an overrepresentation of Afri-
can Americans [23]. Information about comorbid con-
ditions, hospitalization dates, oral and intravenous
medications, quality of life, the delivered dialysis pre-
scription, as well as physician, nurse, dietician and so-
cial worker progress notes are entered into an
electronic medical record. Researchers have used data
from DCI to perform a variety of studies assessing
quality of care and clinical outcomes in patients with
ESRD, including studies of anemia management, adher-
ence to clinical practice guidelines, and factors affecting
important clinical outcomes [24,25]. We have obtained
data on all incident patients within DCI from 2003–Table 2 Characteristics of data sources employed in the DEcID
Data Source Participants Years Setting
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*USRDS=United States Renal Data System.2010 and we have linked data to the USRDS registry to
obtain information on patients’ health conditions and
health care utilization.
United States Renal Data System (USRDS) and Centers for
Medicare and Medicaid Services (CMS)
The United States Renal Data System (USRDS) is a na-
tional data system (funded by the National Institute of
Diabetes and Digestive and Kidney Diseases) that col-
lects, analyzes, and distributes information about ESRD
in the United States. USRDS collaborates with the CMS,
the United Network for Organ Sharing (UNOS), and
the ESRD networks to share datasets. These data com-
prise several sub-files which, when linked, provide
patient-level data on a) demographics, primary diagno-
ses, limited comorbidities and biochemical tests at dia-
lysis initiation; b) health care services utilization and
intravenous medications delivered in dialysis facilities
(Form 2728); c) deaths, including cause of death (Form
2846) and d) outpatient medication use in patients re-
ceiving benefits through Medicare Part D prescription
drug program [26]. These data also include facility-levelE Patient Outcomes in End Stage Renal Disease Study
Data Collection Linkages
ely Medicare Claims National Death Files; Medicare
Part D prescription drug data
ely Clinical Data National Registry (USRDS); National Death








ely Clinical Data National Registry (USRDS);
National Death Files
Table 3 Sample data elements of data sources
Data Element Type Data Source
CHOICE DCI USRDS Registry Cleveland Clinic
CKD Registry
Demographics Present Present Present Present
Outpatient
Medications









Laboratory Data Clinical Data Clinical Data Not Available Clinical Data
Quality of Life Detailed Disease Specific and Global Global Not Available Not Available
Co-morbidity Disease Specific Scale Medical Records Claims Medical Records
Hospitalizations Medical Records Medical Records Claims Medical Records
CVD Events Adjudicated from medical records,
claims
Claims Claims Not Available
Deaths Medical records, Medicare
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formance metrics for all patients receiving ESRD care
under Medicare [1]. We have constructed a cohort of
all US patients initiating dialysis from 2006–2009. For
members of the cohort who initiated dialysis after age
65 and had enrolled in Medicare prior to initiating dialy-
sis, we have also obtained up to two years of pre-dialysis
CMS claims which provides additional ascertainment of
patient comorbidity and health care services utilization
before the initiation of dialysis. We have linked this
cohort to the National Death Index to confirm
patients’ vital status and cause-specific mortality.
Cleveland Clinic Foundation Chronic Kidney Disease
Registry
The Cleveland Clinic Foundation Registry contains clinical
data on over 53,000 patients with CKD based on estimated
glomerular filtration rate (eGFR) or administrative billing
codes obtained through clinical care in the Cleveland
Clinic health care system. Data extracted from patients’
electronic health records include information on patients’
comorbid conditions, laboratory values, and health care
services utilization. These data have been linked to the
National Social Security Death Index as well as the
USRDS data, providing additional information on patients’
vital status as well as their ESRD incidence, and ESRD-
related health and health care utilization [27].
Commonly defined variables
When possible, sub-studies utilize commonly defined
variables to assess patient demographic variables and
comorbid conditions ascertained at studies’ baseline.
Studies also attempt to incorporate similarly defined
morbidity and mortality outcomes and censoring rules
in main analyses.Patient demographics
We ascertain patient demographics (age, gender, race,
education) through both administrative (from USRDS
CMS-2728 form) and clinical data, where available. In
CHOICE, some demographic data collected directly
from the participants are available [22,28].
Comorbid conditions
We utilize validated Medicare claims-based measures to
assess the presence and severity of patients’ comorbid ill-
nesses at the time of dialysis initiation and throughout
the course of treatment [29].
Mortality
We ascertain all-cause mortality and cause-specific
mortality using cause of death information classified
according to the 10th revision of the International Clas-
sification of Disease (ICD-10) obtained from the Na-
tional Death Index, which is commonly used to
ascertain date and cause of death in population-based
studies [30]. We compare information on cause of
death in the USRDS data to information on cause of
death collected from dialysis providers as part of the
USRDS registry (i.e., ESRD Death Notification, Form
CMS-2746) [31]. (Additional file 1)
Morbidity
We ascertain infectious and CVD events (diagnoses and
hospitalizations) and other morbidity (including all cause
hospitalizations and health-related quality of life) using
Medicare and clinical data, where available. We will
obtain data on all hospitalizations from Medicare
claims for all three data sources. We will employ va-
lidated definitions using ICD9-CM codes to deter-
mine infectious and cardiovascular hospitalizations.
Table 4 Expert Stakeholder Advisory Group
Stakeholder Organization Represented
Healthcare Providers American Society of Nephrology,





Federal Government National Institute of Diabetes and Digestive
and Kidney Diseases,
National Heart, Lung and Blood Institute,
Food and Drug Administration
Renal Replacement
Therapy Patients
Transplant Recipient, Patient receiving
Home Hemodialysis
Dialysis Provider Dialysis Clinic Inc.
Payers/Regulators Centers for Medicare and Medicaid Services,
Mid-Atlantic Renal Coalition,
United Health Care, Johns Hopkins
Health Care, CIGNA
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failure and arrhythmia related) will be explored.
Health-related quality of life data are also available in
CHOICE and DCI [32]. (Additional file 1)
Common approaches to statistical analyses
A primary challenge of observational comparative effect-
iveness research is to produce inferences that have
plausibly causal interpretations in order to simulate ran-
domized effectiveness trials. The state of the art for
addressing this challenge is considered by many to be
methods employing inverse probability weighting to de-
velop analytic cohorts whose characteristics and prior
states are balanced across treatment groups, such as
inversely-weighted propensity scoring [33,34] and mar-
ginal structural modeling, which we will employ in pri-
mary analyses [35]. However, because such methods can
exhibit sensitivity to extremes among the weights, we
will also perform sensitivity analyses within and across
data sources to validate main findings and contrast in-
versely probability weighted analyses with generalized
estimating equations [36] based analyses. The latter will
incorporate covariate adjustment to predict treatment
selection with independence working correlation struc-
ture and robust variance correction so as to avoid pro-
pagation of endogeneity [37]. Primary outcomes are
times-to-events; to make feasible the analytic approaches
just described, analyses will be implemented in fine-grain
discrete time (i.e., at intervals of 1, 3, or 6 months) [38].
Analyses will address additional challenges, including
clustering of data within providers, competing and semi-
competing risks (e.g. transplantation, death) [38], effect-
ive summarization of treatment history (e.g., iron dosing
over time), and informative missing data. Analyses for
relative effectiveness of early and later dialysis initiation
pose challenges of immortal time bias [39] and indeter-
minate “origin” for time-to-event analyses (i.e. age at
which a given disease severity is reached that makes a
person a reasonable candidate for dialysis). We are
addressing these challenges through the application of
inverse probability weighted analyses [40].
Stakeholder and external technical expert engagement
panels
We have engaged stakeholders from the ESRD commu-
nity representing patients, providers, payers, and regula-
tors to ensure the relevance of our sub-study questions
and approach, and to help guide dissemination of our
findings. (Table 4) Stakeholders include patients with
kidney disease, a representative from the major dialysis
providers, health care insurers, and representatives from
federal agencies involved in monitoring ESRD treatment.
In addition, we have engaged federal agencies involved
in funding studies in ESRD. We obtained stakeholders’input to modify our preliminary analysis, for example,
expanding our analyses to explore the long-term end
organ toxicity of iron and the effect of patients’ cardio-
vascular volume status on effectiveness of antihyperten-
sive agents. As of date, we have convened 3 face-to-face
stakeholder meetings and will engage stakeholders con-
tinuously throughout the project.
Approach to Sub-studies
Sub-studies comparing effectiveness of antihypertensive
therapies
We are studying the effectiveness of three major antihy-
pertensive medication classes on patients’ morbidity,
mortality and quality of life. Our analyses will account
for several relevant potential confounders and mediators
of the association of antihypertensive medication therapy
choice with patient outcomes, including blood pressure
control, underlying cardiovascular disease and other
comorbidities, and patients’ cardiovascular volume
status.
Antihypertensive therapy
We are assessing whether patients are receiving (either
alone or in combination) one of three major classes of
antihypertensive medications: (a) angiotensin converting
enzyme (ACE) inhibitors or angiotensin II receptor
blocking agents (ARBs); (b) beta receptor blocking
agents; or (c) calcium channel blocking agents. We are
utilizing data from both clinical sources (i.e., medications
abstracted from chart review and dialysis facility medica-
tion lists) and administrative claims (i.e., Medicare Part
D data) to ascertain doses of these medications pre-
scribed to patients over time, as well as medication ad-
herence [26]. We are assessing changes in medications
on a monthly basis, and we are also assessing the pres-
ence of non-standard treatment regimens, including
regimens incorporating medication administration on
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pertensive therapies.
Other Key exposures and correlates
We are measuring other variables which may influence
antihypertensive treatment patterns and effectiveness of
antihypertensive therapy, including: (1) blood pressure
and blood pressure variability, (2) patient volume status,
(3) dialysis dose, (4) dialysis adherence, and (4) the pres-
ence of influential comorbid conditions such as cardio-
vascular disease and congestive heart failure.
Study cohorts
Study cohorts allow for descriptions of individual pa-
tient changes in anti-hypertension therapy regimens
over time as well as to assess the influence of antihy-
pertensive regimens and changes in antihypertensive
regimens on proximal and distal outcomes. We have
created analytic datasets assessing patient time in
discrete time intervals, including 30, 60, and 90 day
windows. Key exposure variables and confounders are
assessed within discrete time intervals, allowing for
time their varying assessment.
Analytic strategies
Our main analyses attempt to identify the comparative
effectiveness of distinct antihypertensive regimens (e.g.
beta-blocker versus ACE or ARB containing regimens)
on outcomes in longitudinal models. We are utilizing
discrete time proportional hazards models to study
the association of time-varying exposures and corre-
lates with outcomes as well as marginal structural
models, which provide an opportunity to account for
time dependent influences of confounders on anti-
hypertension treatment choice through inverse prob-
ability weighting techniques. Our analyses also attempt
to capture differences in the effectiveness of antihyper-
tensive therapies on potential acute (e.g., prevention of
arrhythmias or sudden cardiac death) versus more
chronic (development of cardiovascular disease) out-
comes by incorporating varying lag times (ranging from
no window a 90 day window) between assessments of
exposures and outcomes.
Examples of challenges faced
Defining patients’ blood pressure regimens represents a
key challenge. In exploratory analyses, we identified over
100 distinct combinations of blood pressure medications
used by patients receiving care in DCI. Many patients
received more than one of the key antihypertensive ther-
apies of interest, while others received numerous blood
pressure combination regimens that changed over time.
In order to provide decision makers with evidence they
will deem usable, we will simplify our definitions ofregimens to ensure they directly address key decisions
clinicians would confront commonly in clinical practice
(e.g., a decision to implement a regimen that contains a
beta blocker versus a regimen that contains an ACE in-
hibitor or a regimen that contains both agents).
Sub-studies comparing effectiveness of early versus later
dialysis initiation
We are studying the effects of starting dialysis early ver-
sus later on patients’ of morbidity, mortality, and quality
of life outcomes. Using data collected prior to patients’
dialysis initiation when possible, we will account for
patients’ clinical conditions that could lead to earlier dia-
lysis initiation (e.g., fluid overload from congestive heart
failure). We also seek to account for the contribution of
local or regional practice variations in dialysis care
[23,41].
Early versus later timing of dialysis initiation
We define early versus later dialysis initiation based on
pre-defined thresholds of estimated glomerular filtration
rate (eGFR) (e.g., eGFR greater than 10ml/min/1.73m2
versus less than 10ml/min/1.73m2). We obtain (when
available) information on GFR at dialysis initiation from
provider questionnaires (i.e., obtained from USRDS
CMS form 2728). For analyses among patients with pre-
dialysis CKD (i.e., stage 4 CKD, in the Cleveland Clinic
registry), we obtain information on eGFR from labora-
tory records extracted from patients’ electronic health
records.
Other Key exposures and correlates
We are also measuring other variables that may influ-
ence patients’ need for early dialysis, including the bur-
den and severity of comorbid illnesses (e.g., congestive
heart failure) and the occurrence of medical events (e.g.,
hospitalizations) in the pre-dialysis period. When data
are available, we also assess the frequency of patients’
utilization of pre-dialysis nephrology care and their
preparation for renal replacement therapy (e.g., fistula
placement) prior to dialysis initiation.
Construction of study cohorts
We are constructing cohorts to allow for descriptions of
pre-dialysis factors influencing the initiation of early dia-
lysis when possible. This includes a cohort of patients
initiating dialysis who have pre-dialysis CMS claims
linked to their CMS dialysis health claims (in USRDS) as
well as a cohort of patients seen in nephrology clinics
who have dialysis CMS claims linked to their pre-
dialysis health records (in Cleveland Clinic). In cases
where pre-dialysis claims are not available, we are using
data collected from physicians at the time of patients’
dialysis initiation (i.e., from CMS-2728 form).
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Our analyses address limitations in previous observa-
tional studies of the comparative effectiveness of early
versus later dialysis initiation [42-46]. One key limitation
of prior studies is their inability to account for differ-
ences in patients’ pre-dialysis health and health care
utilization which may have influenced their initiation of
dialysis. We strive to construct cohorts with information
on patients’ pre-dialysis health and health care utiliza-
tion whenever possible. We are employing propensity
score methods and instrumental variables to account
for observed and unobserved cofounders previously
observed to predict between early dialysis initiation and
poor outcomes. We are also using newly developed
modeling techniques [47] to address biases (e.g., im-
mortal person time) associated with observing patients
only from the time of their earlier versus later dialysis
initiation to outcomes.
Example of challenges faced
A key challenge we face in constructing cohorts is the
problem of adequately capturing patients’ pre-dialysis
health and trajectory of CKD progression prior to dialy-
sis initiation. For instance, patients may suffer from
symptoms (e.g., extreme fatigue or weight loss due to
poor appetite) that could heavily influence patients’ and
providers’ preferences for initiating dialysis. To address
this challenge, we are attempting to capture pre-dialysis
comorbidity by utilizing datasets that collect information
on pre-dialysis health status as assessed in billing data
and medical records. We are adapting previously vali-
dated comorbidity instruments, and trying to capture
measures of the frequency or intensity of health care
utilization (e.g., number pre-dialysis hospitalizations),
which we hypothesize could reflect patients’ health
declines and perceived need for earlier dialysis.
Sub-studies comparing effectiveness of anemia
management strategies
We are studying the safety and effectiveness of various
iron dosing strategies in the care of dialysis patients. We
will consider both the risk of infectious morbidity and
mortality related to iron administration as well as the
risk of end-organ damage (i.e., from iron deposition).
We will assess effectiveness of various dosing strategies
in terms of the achievement of hemoglobin treatment
goals [48], erythropoietin stimulating agent use and the
frequency of blood transfusions.
Iron administration
We are assessing cumulative iron utilized over short and
longer time periods as well as the pattern of iron admin-
istration (e.g., intermittent bolus administration versus
maintenance dosing). We will ascertain iron doses fromboth clinical data (i.e., medications abstracted from elec-
tronic chart review and dialysis facility medication lists)
and administrative billing data (i.e., dialysis intravenous
medication claims from CMS).
Other Key exposures and correlates
We are measuring other variables that may influence
iron dosing patterns and effectiveness of iron therapy,
including (1) the presence of inflammation or infection,
(2) patient comorbidity, (3) use of other medications to
treat anemia (i.e., erythropoiesis stimulating agents), and
(4) patients’ response to anemia therapy.
Construction of study cohorts
We are constructing study cohorts to allow for descrip-
tions of individual patient changes in iron therapy regi-
mens over time as well as to assess the influence of iron
dose and changes in dosing regimens on proximal and
distal outcomes. We have created analytic datasets asses-
sing patient time in discrete time intervals, including 30,
60, 90, and 180 day windows. Key exposure variables
and confounders are assessed within discrete time inter-
vals, allowing for their time varying assessment.
Analytic strategies
Our main analyses will compare the effectiveness of
varying levels of iron dose on outcomes in longitudinal
models. We are utilizing discrete time proportional
hazards models to study the association of time-varying
exposures and correlates with outcomes as well as mar-
ginal structural models, which provide an opportunity to
account for time dependent influences of confounders
on iron therapy. Our analyses will assess differences in
the effectiveness of iron therapies on acute (e.g., infec-
tious outcomes) and more chronic (e.g., cardiovascular
disease) outcomes by incorporating varying lag times
(ranging from no window a 90 day window) between
assessments of exposures and outcomes.
Example challenges
Evaluating the short versus longer-term toxicity of iron
presents a challenge. While cardiovascular events and
iron deposition disorders may represent intermediate
and long term outcomes, acute infectious hospitaliza-
tions may be proximally related to iron administration.
Our analyses will calculate total iron exposure over vary-
ing discrete time periods (i.e., 30, 60, 90, or 180 days)
and incorporate a time lag of up to 30 days to help dis-
tinguish short versus long-term effect of iron on out-
comes. Another challenge is the incorporation of
laboratory values (e.g., transferrin saturation or ferritin),
which are measured at infrequent intervals but which in-
fluence physicians’ administration of iron. We have cre-
ated longer rolling ‘windows’ over which we observe
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identifying both average values as well as most recently
obtained values as they may be most influential on phy-
sicians’ iron prescribing patterns.
Ethics and dissemination of study findings
All data sources are de-identified prior to analyses. We
are performing all analyses of USRDS, CHOICE, and
DCI data with the approval of the Johns Hopkins Insti-
tutional Review Board. Analyses of Cleveland Clinic data
are performed at the Cleveland Clinic with approval of
the Cleveland Clinic Institutional Review Board. We will
work with our Stakeholder Panel to provide insight into
optimal avenues and formats (e.g., trade publications, so-
cial media) for dissemination of our findings. We will
also work with the Eisenberg Center within AHRQ to
disseminate our study findings widely among stake-
holders in the ESRD community.
Discussion
There is a great need for studies comparing the effect-
iveness of common treatment strategies employed in
the care of patients with ESRD. The DEcIDE Patient
Outcomes in End Stage Renal Disease Study addresses
questions commonly confronted by decision makers
(including patients, health care providers, payers and
policy-makers) involved in ESRD care.
Several aspects of the DEcIDE Patient Outcomes in
End Stage Renal Disease Study distinguish it from other
ongoing observational studies. First, our use of clinical
and administrative data will facilitate our study of actual
clinical practice patterns, enhancing the relevance of our
findings to decision makers. Second, our data incorpor-
ate both clinical and administrative information, enhan-
cing the specificity with which we can classify key
exposures, confounders, and outcomes. Examination of
four complementary cohorts will enable triangulation of
results. If consistent findings are obtained, this will en-
hance decision makers’ confidence to act on evidence
emerging from our studies. Third, our continuous en-
gagement of stakeholders throughout the conduct of the
study is novel among ESRD studies, and will enhance
how the ESRD community values and integrates our
findings. Fourth, our nationally representative cohorts
feature some data linkages that have not previously been
performed in comparative effectiveness studies among
ESRD patients. Studies previously assessing cause spe-
cific mortality in ESRD have relied on dialysis physician
reports in CMS reports (Form 2746). Our data linkages
with the National Death Index for determination of
cause specific mortality will help us validate these
reports and may enhance the comparability of our find-
ings to epidemiological studies in other areas. Finally,
our use of novel strategies to overcome limitations (e.g.,immortal person time in assessments of early versus
later dialysis initiation) of prior studies may help to
better inform previously unanswered questions in
ESRD care.
In conclusion, the DEcIDE Patient Outcomes in End
Stage Renal Disease Study is funded to address gaps in
evidence regarding the effectiveness of common treat-
ment strategies employed in ESRD care. Study of these
strategies in four representative US cohorts of patients
with kidney disease using rigorous statistical method-
ology and ongoing engagement of stakeholders in the
ESRD community enhances the likelihood these studies
will yield findings deemed relevant and useful to deci-
sion makers in ESRD care.
Additional file
Additional file 1: Appendix.
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